ZYUS Life Sciences (TSXV:ZYUS) EBIT per Share : C$-0.66 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences EBIT per Share?

ZYUS Life Sciences's EBIT per Share for the three months ended in Mar. 2024 was C$-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.66.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for ZYUS Life Sciences's EBIT per Share or its related term are showing as below:

TSXV:ZYUS's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

ZYUS Life Sciences's EBIT for the three months ended in Mar. 2024 was C$-3.17 Mil.

ZYUS Life Sciences EBIT per Share Historical Data

The historical data trend for ZYUS Life Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences EBIT per Share Chart

ZYUS Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

EBIT per Share

-0.30

-0.28

-0.81

ZYUS Life Sciences Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial					-0.05	-0.13	-0.06	-0.43	-0.05

ZYUS Life Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

ZYUS Life Sciences's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-45.167	/	56.122
=	-0.80

ZYUS Life Sciences's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.17	/	70.847
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.66

ZYUS Life Sciences (TSXV:ZYUS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

ZYUS Life Sciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ZYUS Life Sciences (TSXV:ZYUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ZLSCF:USA

Address

407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8

Website

https://www.zyus.com

ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.

Executives

John Michael Hyshka

Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines